Acquisition of Molecular Insight Pharmaceuticals, Inc (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Apr. 30, 2014	Dec. 31, 2013	Jan. 18, 2013
Business Acquisition [Line Items]
Original Shares Issued For Acquisition					4,566,210
Shares For Acquisition Held In Escrow					500,000
Closing price of Progenics' common shares					$ 2.83
Shares For Acquisition Returned From Escrow	93,847		19,770
Maximum Milestone Payment Specified Commercial Events	$ 23,000,000
Maximum Milestone Payment For Achieving Sales Targets	70,000,000
Business Acquisition, Cost of Acquired Entity, Transaction Costs		750,000
Equity issuance costs in connection with acquisition of subsidiary	0	45,000
Goodwill	7,702,000			7,702,000
Business Acquisition Transaction Costs Excluded From Pro Forma Information		750,000
Molecular Insight Pharmaceuticals Inc [Member]
Business Acquisition [Line Items]
Business Acquisition Contributed Revenue	1,012,000	329,000
Business Acquisition Contributed Net Loss	439,000	3,175,000
Total acquisition consideration paid					27,165,000
Business Acquisition Tangible And Intangible Assets Acquired Liabilities Assumed					19,463,000
Goodwill					$ 7,702,000